top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

97.70 -1.27 (-1.28%)
Streaming Delayed Price Updated: 12:24 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESS Newswire
News headline image
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Via ACCESS Newswire
News headline image
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
Via ACCESS Newswire
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Via ACCESS Newswire
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Via ACCESS Newswire
News headline image
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Via ACCESS Newswire
News headline image
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Via ACCESS Newswire
News headline image
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Via ACCESS Newswire
News headline image
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
Via ACCESS Newswire
News headline image
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Via ACCESS Newswire
News headline image
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Via ACCESS Newswire
News headline image
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
Via ACCESS Newswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page